Abstract
Büyükçelik et al. raise a valid question regarding the relation between hyperglycemia and dose reduction during chemotherapy with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) for the treatment of acute lymphocytic leukemia. We reviewed the data and found that 62% of patients with hyperglycemia (defined as a random serum glucose level of ≥ 200 mg/dL on 2 or more determinations during the first 30 days of treatment) had a dose reduction at some time during treatment, compared with 60% of patients without hyperglycemia. Therefore, there does not appear to be an association between hyperglycemia and the risk for reduction in dose intensity in this patient population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
